公开(公告)号：US20210164996A1

公开(公告)日：2021-06-03

申请号：US17046473

申请日：2019-04-12

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Philip PRESHAW ,  John J TAYLOR ,  Michael Alex VAN HARTSKAMP

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Profilin and S100 calcium-binding protein A9 (S100A9). Another combination is Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.

公开(公告)号：US20230393149A1

公开(公告)日：2023-12-07

申请号：US18236453

申请日：2023-08-22

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Philip PRESHAW ,  John J. TAYLOR

IPC: G01N33/68 ,  G16H10/40

CPC classification number: G01N33/6893 ,  G16H10/40 ,  G01N2333/4737 ,  G01N2333/4753 ,  G01N2333/545 ,  G01N2800/18 ,  G01N2800/60

Abstract: Disclosed is an in vitro method for assessing the presence of gingivitis in a human subject. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a saliva sample of the subject the concentrations are measured of the proteins Hepatocyte growth factor (HGF) and Interleukin-1β (IL-1β), and at least one of C reactive protein (CRP) and Haemoglobin. Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with the absence of gingivitis or periodontitis. The comparison allows to assessing whether the testing value is indicative of the presence of gingivitis in said subject. Thereby, typically, a testing value reflecting a joint concentration above the joint concentration reflected by the threshold, is indicative of the presence of gingivitis.

公开(公告)号：US20210181209A1

公开(公告)日：2021-06-17

申请号：US16758902

申请日：2018-10-18

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Supriyo CHATTERJEA ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Philip PRESHAW ,  John J TAYLOR

IPC: G01N33/68

Abstract: Disclosed is a system, a kit, a use and an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The system and method are based on the insight to apply a clustering technique to a reference set of patient data, and then further discriminating the sets of bio markers to be applied. The clusters are determined on the basis of the biomarkers Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), and Matrix metalloproteinase 9 (MMP9). The actual classification of the patient is done on the basis of the measurement of the concentrations of either of two sets of biomarkers. For one cluster these are Interleukin-1β (IL1β), Interleukin-6 (IL6), and Collagen Telopeptide. For the other cluster, these are HGF and metallopeptidase inhibitor 1 (TIMP1).

公开(公告)号：US20230417769A1

公开(公告)日：2023-12-28

申请号：US18243159

申请日：2023-09-07

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Bart Jacob BAKKER ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Philip PRESHAW ,  John TAYLOR

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4753 ,  G01N2333/96494 ,  G01N2800/18

Abstract: Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and/or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.

公开(公告)号：US20210164995A1

公开(公告)日：2021-06-03

申请号：US17046397

申请日：2019-04-10

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Philip PRESHAW ,  John TAYLOR ,  Michael Alex VAN HARTSKAMP

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human patient has gingivitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from gingivitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and S100 calcium-binding protein A8 (S100A8), and at least one of Hemoglobin subunit beta (Hb-beta), Keratin 4 (K-4) and Pyruvate Kinase (PK). Another combination is Alpha-1-acid glycoprotein (A1AGP), Hemoglobin subunit beta (Hb-beta) and Keratin 4 (K-4). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with gingivitis. The comparison allows assessing whether the testing value is indicative of the presence of gingivitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of gingivitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for gingivitis in said patient.

公开(公告)号：US20210109113A1

公开(公告)日：2021-04-15

申请号：US17046430

申请日：2019-04-11

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Philip PRESHAW ,  John J. TAYLOR ,  Michael Alex VAN HARTSKAMP

IPC: G01N33/68 ,  G01N33/573 ,  G16H50/20 ,  G16H50/30

Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of two or more of the proteins Matrix metalloproteinase-8 (MMP-8), Matrix metalloproteinase-9 (MMP-9), Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.

公开(公告)号：US20200174019A1

公开(公告)日：2020-06-04

申请号：US16615429

申请日：2018-05-24

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Bart Jacob BAKKER ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Philip PRESHAW ,  John TAYLOR

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and/or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.

公开(公告)号：US20250020664A1

公开(公告)日：2025-01-16

申请号：US18758512

申请日：2024-06-28

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Supriyo CHATTERJEA ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Michael Alex VAN HARTSKAMP ,  Philip PRESHAW ,  John TAYLOR

IPC: G01N33/68 ,  G16H50/20

Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Interleukin-1β (IL-1β), Matrix metalloproteinase-9 (MMP-9) and at least one of the proteins: Interleukin-6 (IL-6), and Matrix metalloproteinase-3 (MMP-3). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

公开(公告)号：US20210382069A1

公开(公告)日：2021-12-09

申请号：US17045312

申请日：2019-04-02

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Philip PRESHAW ,  John J TAYLOR ,  Michael Alex VAN HARTSKAMP

IPC: G01N33/68 ,  C12N9/12 ,  B01L3/00

Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least two of Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

公开(公告)号：US20210164994A1

公开(公告)日：2021-06-03

申请号：US17045344

申请日：2019-04-02

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Philip PRESHAW ,  John TAYLOR ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Marinus Karel Johannes DE JAGER

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Interleukin-1-beta (I-1β) and 5 Matrix metalloproteinase-8 (MMP-8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of 10 periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.